Opportunities and Challenges in Teams Migrations with Brian Gregory

Communication and collaboration tools have never been more valuable for organizations. The need for them to be adaptable and flexible is also critical.

Does it make sense to migrate to a unified platform that integrates all communication and collaboration in one? And what challenges do companies face?

Sharing his expertise on the subject is Brian Gregory, Channel Marketing at Ribbon Communications.

“There are so many options on the market, but there’s a considerable amount of growth for Teams. One, it’s part of the Microsoft suite bundle, so the base version is free. Another reason is they’ve been in the space for over a decade,” Gregory said.

Gregory noted that moving from one platform to another was once an arduous task of business case justification, executive sponsorship and testing. COVID-19 changed that.

“Companies needed something quickly, and Teams gets the work done. A new question is, ‘Should we integrate voice, too?’,” he added.

Unified communications platforms live entirely in the cloud. Voice was often still an on-premises solution. Now, it’s thrown into the cloud, too, which can have IT teams concerned about security.

Ribbon provides session border controllers (SBCs) to mitigate risk.

“An SBC is a firewall for voice. It’s purpose-built for VoIP. It’s a buffer between the provider network and yours. It’s to protect against any infiltration to the network,” Gregory explained.

Companies migrating to the cloud but still have legacy interfaces can use SBCs, as well. The company also offers Ribbon Connect for Microsoft Teams. Ribbon Connect enables you to connect legacy voice environments with Teams.

Technology like this can make transitions easier. It also makes sense in today’s environment, and this movement is a trend that will continue. Gregory also noted that voice still has a place in business operations, but peer-to-peer communication is much different.

“We’re not making calls like in the past, so the growth of this collaboration platforms will continue. What we do is help enterprises transition smartly,” he said.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

Immuno-Oncology
Shaping the Future of Cancer Care Through Immuno-Oncology
April 19, 2025

In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed…

Read More
Evolving Biomarkers: Charting the Future of Precision Medicine
April 19, 2025

In a rapidly shifting landscape of personalized medicine, biomarkers have become central to shaping the way drug development and clinical trials unfold. From predicting therapeutic response to identifying optimal patient populations, the complexity and scope of biomarker use has increased alongside technological advances. A key success story like the BCR-ABL biomarker in chronic myeloid leukemia…

Read More
Drug Discovery
Exploring Artificial Intelligence in Drug Discovery
April 19, 2025

Artificial intelligence is rapidly reshaping the drug discovery process, moving from augmenting research to actively driving innovation. As biotech companies face soaring R&D costs and long development cycles, AI promises a breakthrough: slashing drug development time by nearly half while improving accuracy in identifying promising compounds. With global pharmaceutical R&D spending projected to exceed $230…

Read More
KRAS
Pioneering Strategies to Unlocking the Potential of KRAS
April 18, 2025

Once labeled “undruggable,” KRAS has emerged as one of oncology’s most promising—yet complex—targets. With nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harboring KRAS mutations, the need for effective therapies is urgent. Recent FDA approvals of KRAS G12C inhibitors have signaled a new era, but the rise of resistance and diverse…

Read More